Reaction

Linear Iga Disease reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,643 reports · 53 co-occurring drugs

As of the last recalculation, Linear Iga Disease appears in 1,643 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is VANCOMYCIN HYDROCHLORIDE (PRR 220.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Vancomycin Hydrochloride676220.1222.3
Vancomycin592202.3204.4
Daspone6283.884.3
Dapsone Gel, 5%6283.784.3
Piperacillin And Tazobactam7780.080.4
Dapsone6276.476.9
Piperacillin Sodium,Tazobactam Sodium13268.568.8
Piperacillin Sodium And Tazobactam Sodium8255.755.9
Cefazolin3245.345.5
Gentamicin4443.843.9
Rifampicin3342.142.3
Cefazolin Sodium3739.839.9
Gentamicin Sulfate4738.838.9
Meropenem8535.335.4
Sirolimus3634.634.7
Cefepime3027.027.0
Ceftriaxone6224.824.9
Tobramycin Solution2324.624.6
Cefepime Hydrochloride3024.024.1
Tobramycin Sulfate2323.923.9
Metronidazole Topical8423.523.5
Ceftriaxone Sodium6522.322.4
Daptomycin1622.222.2
Metronidazole8818.418.4
Ampicillin1116.917.0
Ampicillin Sodium1116.917.0
Cefuroxime1516.816.8
Rifampin1916.716.7
Micafungin Sodium1116.516.6
Ciprofolxacin7313.513.5
Ciprofloxacin Tablets7313.513.5
Mupirocin1413.313.3
Mupirocin Calcium1413.013.0
Terbinafine Hydrochloride912.912.9
Febuxostat Tablets 40 Mg1012.512.5
Febuxostat Tablets 80 Mg1012.512.5
Phenytoin2012.312.3
Tobramycin2312.312.3
Ketoprofen1211.711.7
Amoxicillin6711.511.6
Amlodipine Besylate And Valsartan1011.511.5
Amikacin1511.211.2
Desloratadine910.710.7
Ciprofloxacin7310.510.5
Amoxicillin And Clavulanate Potassium2210.410.4
Meloxicam4610.310.3
Ciprofloxacin Hydrochloride7510.210.2
Isosorbide Mononitrate159.29.2
Levofloxacin408.68.6
Levofloxacin In 5% Dextrose408.68.6
Febuxostat107.67.6
Deferasirox115.35.3
Vigabatrin32.62.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.